子宮頸がん検診・診断・前がん異形成病変治療の世界市場 (種類別・地域別)：セグメント別予測 (2025年～2035年)

子宮頸がん検診・診断・前がん異形成病変治療市場の成長と動向：

Grand View Research, Incの最新レポートによると、世界の子宮頸がん検診・診断・前がん異形成病変治療の市場規模は2035年までに156億7,504万米ドルに達すると予測され、2025年から2035年までのCAGRは5.90％で成長すると予測されています。

市場成長の原動力は、技術の進歩、意識の向上、予防医療への強い関心です。医療アクセスの格差や子宮頸がんの継続的な負担といった課題は根強いが、連邦政府機関、医療提供者、地域組織の協力的な取り組みにより、治療成績の向上が促進されています。子宮頸がんの罹患率と死亡率を減少させるには、早期発見、革新的な治療法、公平な医療アクセスへの継続的な投資が不可欠です。市場が拡大する中、利害関係者は費用対効果の高い解決策と革新的な検診技術を優先し、多様な集団に包括的に適用されるようにしなければならないです。

先進的な検診・治療技術の急速な導入は、市場拡大の主な要因となっています。例えば、2024年7月、アスピラス・ウッドラフ・クリニックでは、Loop Electrosurgical Excision Procedure（LEEP）装置の導入により、レイクランドの女性が最先端の子宮頸部治療を受けられるようになりました。この技術は子宮頸部異形成の治療における大きな前進であり、理事会認定の婦人科医であるジョエル・ウェンランド医師は、子宮頸がん予防における重要な役割を強調しています。同様に、2021年1月、プレグナ・インターナショナル社は、クライオポップ凍結療法装置を発売し、女性ヘルスケアにおけるリーダーとしての地位を強化しました。Jhpiego社との提携により開発されたCryoPopは、子宮頸がん撲滅に向けたWHOの世界戦略に沿い、世界中で子宮頸部前がん病変治療へのアクセスを向上させます。

子宮頸がん検診・治療業界における最も大きな成長機会のひとつは、費用対効果が高く、利用しやすい検診技術の開発と導入です。高所得国における子宮頸がん罹患率の低下において、パップスメアは歴史的に重要な役割を果たしてきたが、専門的な人材と検査施設のインフラに依存しているため、資源に制約のある環境ではその実現性に限界があります。このような課題に対処するため、世界保健機関（WHO）は、より利用しやすい検診方法を含めるようガイドラインを更新し、十分なサービスを受けていない地域における検診率の向上と早期発見の促進を目指しています。WHOの子宮頸がん撲滅のための世界戦略は、2030年までに35歳と45歳の女性の70％を高性能検査で検診することを目指しています。このイニシアチブは、世界の検診プログラムの拡大に対するWHOのコミットメントを浮き彫りにしており、市場の成長可能性を高めています。

パップスメアなどの従来の子宮頸がん検診法は、長い間ゴールドスタンダードでした。しかし、液体ベースの細胞診や高リスクHPV DNA検査などの技術的進歩によって補完されるようになってきています。これらのアプローチは、サンプルの質を向上させ、診断精度を高め、所要時間を短縮し、早期発見をより効果的なものにしています。

子宮頸がん診断における人工知能（AI）の統合はゲームチェンジャーであり、検診の効率に革命をもたらしました。AIを活用したツールは現在、細胞診画像を高精度で分析し、前がん病変やがん病変を示す可能性のある異常細胞を特定することができます。例えば、AIを搭載した診断システムは、デジタル化された細胞診スライドを自動的に評価し、さらなる臨床検査のために潜在的な異常のフラグを立てることができます。これはヒューマンエラーを減らすだけでなく、診断プロセスを迅速化し、より迅速な医療介入につながります。

AIの影響は診断にとどまらず、治療計画にも及びます。機械学習と予測分析により、ヘルスケアプロバイダーは病変の進行をより適切に評価し、個人に合わせた治療アプローチを提供することができます。LEEPや凍結療法などの技術は、AIの精度から大きな恩恵を受け、低侵襲で非常に効果的な介入と回復時間の短縮を保証します。ヘルスケアのインフラが限られている地域では、AI主導のソリューションが検診プログラムを効率的に拡大し、高品質の診断と治療をより身近なものにします。

子宮頸がん検診・診断・前がん異形成病変治療市場：分析概要

• 種類別では、子宮頸がん検診分野が2024年に48.29%の最大収益シェアで市場をリードし、予測期間中に最も速いCAGRで成長すると予測されます。子宮頸がん検診は、早期発見と予防のために不可欠であり、精度、アクセス性、患者の転帰を高めるためにさまざまな機器や技術を活用しています。従来のパップスメア採取ツールは、特に高度な診断インフラが整っていない地域では、依然として検診の要となっています。
• 子宮頸がん診断市場は、生検装置や膣鏡の進歩に加え、これらの技術に対する採用や需要が増加していることから、予測期間中に大幅なCAGRが見込まれます。2024年12月、連邦首都圏管理局は、女性の子宮頸がんの早期発見と治療を強化するために設計されたコルポスコピー装置を導入しました。この画期的な取り組みは、同地域のヘルスケア提供に革命をもたらすと期待されています。
• 北米が2024年に41.17％の最大売上シェアで市場を独占しました。北米は過去数十年間、主に大規模な子宮頸がん検診プログラムを通じて、子宮頸がんの罹患率と死亡率の減少において目覚ましい進歩を遂げてきました。これらのイニシアチブは、パップスメア（細胞診）と、最近ではヒトパピローマウイルス（HPV）検査に大きく依存しています。しかし、多くの地域で全体的な検診率が高いにもかかわらず、検診への参加とフォローアップケアにおいて、特に十分なサービスを受けていない集団の間で格差が残っています。こうした格差に対処するため、北米中のヘルスケアシステムが革新的なソリューションを採用しています。コバスHPVアッセイやBDオンクラリティHPVアッセイのようなHPV自己採取検査の最近のFDA承認は、不快感、文化的過敏性、または過去のトラウマのために従来の骨盤内検査を避ける可能性のある女性にとって、有望な選択肢を提示するものです。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 子宮頸がん検診・診断・前がん異形成病変治療市場：変動要因・傾向・範囲

• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
  • 市場機会の分析
• 子宮頸がん検診・診断・前がん異形成病変治療市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 子宮頸がん検診・診断・前がん異形成病変治療市場：定性データ分析

• 子宮頸がん検診ガイドライン
• 子宮頸がん検診の活用
• WHO・その他の政策委員会の立場
• 子宮頸がん検診の障壁

第5章 子宮頸がん検診・診断・前がん異形成病変治療市場：市場動向分析

• 新興技術とイノベーションの動向
• 償還の情勢
• 子宮頸がんの発生率と有病率
• 総対象人口
• HPVワクチン接種を受けた集団の動向の評価

第6章 子宮頸がん検診・診断・前がん異形成病変治療市場：種類別の推定・動向分析

• 市場シェア：種類別（2024年・2035年）
• セグメント別のダッシュボード
• 子宮頸がん検診・診断・前がん異形成病変治療市場：種類別の展望
• 子宮頸がん検診
  • パップスメア採取器具
  • HPV検査プラットフォーム
  • サイトブラシ
  • 自己採取キット
  • その他
• 子宮頸がん診断
  • 膣鏡
  • 子宮頸部生検装置
  • AI画像搭載コルポスコープ（デジタル）
  • その他
• 前がん病変治療
  • LEEP（ループ電気外科切除術）装置
  • 凍結療法
  • 熱アブレーション
  • その他

第7章 子宮頸がん検診・診断・前がん異形成病変治療市場：地域別の推定・動向分析（製品別、種類別、最終用途別）

• 市場シェア分析：地域別（2024年・2035年）
• 市場ダッシュボード：地域別
• 世界市場のスナップショット：地域別
• 市場規模の予測と動向分析（2018～2035年）
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 最近の動向と影響分析：主要市場参入企業別
• 企業/競合の分類
• 主要企業の市場シェア/ポジション分析（2024年）
• 企業プロファイル
  • F. Hoffmann-La Roche
  • BD
  • Abbott
  • QIAGEN
  • Hologic, Inc.
  • CooperSurgical Inc.
  • MedGyn Products, Inc
  • WISAP Medical Technology GmbH
  • Liger Medical
  • Utah Medical Products, Inc.

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 North America Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 4 US Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 5 Canada Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 6 Mexico Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 7 Europe Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 8 UK Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 9 Germany Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 10 France Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 11 Italy Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 12 Spain Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 13 Denmark Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 14 Sweden Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 15 Norway Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 16 Asia Pacific Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 17 Japan Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 18 China Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 19 India Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 20 Australia Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 21 South Korea Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 22 Thailand Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 23 Latin America Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 24 Brazil Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 25 Argentina Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 26 MEA Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 27 South Africa Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 28 Saudi Arabia Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 29 UAE Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)
• Table 30 Kuwait Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market estimates and forecasts, by type, 2018 - 2035 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market outlook
• Fig. 9 Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market driver impact
• Fig. 15 Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market restraint impact
• Fig. 16 Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market strategic initiatives analysis
• Fig. 17 Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market: Type analysis
• Fig. 18 Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market: Type outlook and key takeaways
• Fig. 19 Cervical cancer screening market estimates and forecast, 2018 - 2035
• Fig. 20 Pap Smear Collection Devices market estimates and forecast, 2018 - 2035
• Fig. 21 HPV Testing Platforms market estimates and forecast, 2018 - 2035
• Fig. 22 Cytobrush market estimates and forecast, 2018 - 2035
• Fig. 23 Self-collection kits market estimates and forecast, 2018 - 2035
• Fig. 24 Others market estimates and forecast, 2018 - 2035
• Fig. 25 Cervical cancer diagnostics market estimates and forecast, 2018 - 2035
• Fig. 26 Colposcopes market estimates and forecast, 2018 - 2035
• Fig. 27 Cervical biopsy devices market estimates and forecast, 2018 - 2035
• Fig. 28 Colposcopes with AI imaging (Digital) market estimates and forecast, 2018 - 2035
• Fig. 29 Others market estimates and forecast, 2018 - 2035
• Fig. 30 Pre-cancerous lesion treatment market estimates and forecast, 2018 - 2035
• Fig. 31 LEEP (loop electrosurgical excision procedure) machine market estimates and forecast, 2018 - 2035
• Fig. 32 Cryotherapy market estimates and forecast, 2018 - 2035
• Fig. 33 Thermal ablation market estimates and forecast, 2018 - 2035
• Fig. 34 Others market estimates and forecast, 2018 - 2035
• Fig. 35 Global Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market: Regional movement analysis
• Fig. 36 Global Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market: Regional outlook and key takeaways
• Fig. 37 Global Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market share and leading players
• Fig. 38 North America: SWOT
• Fig. 39 Europe SWOT
• Fig. 40 Asia Pacific SWOT
• Fig. 41 Latin America SWOT
• Fig. 42 MEA SWOT
• Fig. 43 North America market estimates and forecasts, 2018 - 2035
• Fig. 44 US market estimates and forecasts, 2018 - 2035
• Fig. 45 Canada market estimates and forecasts, 2018 - 2035
• Fig. 46 Mexico market estimates and forecasts, 2018 - 2035
• Fig. 47 Europe market estimates and forecasts, 2018 - 2035
• Fig. 48 UK market estimates and forecasts, 2018 - 2035
• Fig. 49 Germany market estimates and forecasts, 2018 - 2035
• Fig. 50 France market estimates and forecasts, 2018 - 2035
• Fig. 51 Italy market estimates and forecasts, 2018 - 2035
• Fig. 52 Spain market estimates and forecasts, 2018 - 2035
• Fig. 53 Denmark market estimates and forecasts, 2018 - 2035
• Fig. 54 Sweden market estimates and forecasts, 2018 - 2035
• Fig. 55 Norway market estimates and forecasts, 2018 - 2035
• Fig. 56 Asia Pacific market estimates and forecasts, 2018 - 2035
• Fig. 57 China market estimates and forecasts, 2018 - 2035
• Fig. 58 Japan market estimates and forecasts, 2018 - 2035
• Fig. 59 India market estimates and forecasts, 2018 - 2035
• Fig. 60 Thailand market estimates and forecasts, 2018 - 2035
• Fig. 61 South Korea market estimates and forecasts, 2018 - 2035
• Fig. 62 Australia market estimates and forecasts, 2018 - 2035
• Fig. 63 Latin America market estimates and forecasts, 2018 - 2035
• Fig. 64 Brazil market estimates and forecasts, 2018 - 2035
• Fig. 65 Argentina market estimates and forecasts, 2018 - 2035
• Fig. 66 Middle East and Africa market estimates and forecasts, 2018 - 2035
• Fig. 67 South Africa market estimates and forecasts, 2018 - 2035
• Fig. 68 Saudi Arabia market estimates and forecasts, 2018 - 2035
• Fig. 69 UAE market estimates and forecasts, 2018 - 2035
• Fig. 70 Kuwait market estimates and forecasts, 2018 - 2035
• Fig. 71 Market share of key market players- Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment market
• Fig. 72 Key Company Categorization
• Fig. 73 Company Market Share/Position Analysis, 2024
• Fig. 74 Strategic Framework

Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Growth & Trends:

The global cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market size is anticipated to reach USD 15,675.04 million by 2035 and is projected to grow at a CAGR of 5.90% from 2025 to 2035, according to a new report by Grand View Research, Inc. The market growth is driven by technological advancements, increased awareness, and a strong focus on preventive care. Despite persistent challenges such as disparities in healthcare access and the ongoing burden of cervical cancer, collaborative efforts among federal agencies, healthcare providers, and community organizations are fostering improved outcomes. Continued investment in early detection, innovative treatment options, and equitable healthcare access will be critical in reducing cervical cancer incidence and mortality. As the market expands, stakeholders must prioritize cost-effective solutions and innovative screening technologies to ensure comprehensive coverage across diverse populations.

The rapid adoption of advanced screening and treatment technologies has been a key driver of market expansion. For instance, in July 2024, women in Lakeland gained access to state-of-the-art cervical care at Aspirus Woodruff Clinic with the introduction of a Loop Electrosurgical Excision Procedure (LEEP) machine. This technology marks a major step forward in the treatment of cervical dysplasia, with Dr. Joelle Wennlund, a Board-certified Gynecologist, emphasizing its critical role in cervical cancer prevention. Similarly, in January 2021, Pregna International Ltd. reinforced its position as a leader in women's healthcare by launching the CryoPop cryotherapy device. Developed in partnership with Jhpiego, CryoPop enhances accessibility to cervical pre-cancerous lesion treatment worldwide, aligning with WHO's global strategy for cervical cancer elimination.

One of the most significant growth opportunities in the cervical cancer screening and treatment industry is the development and implementation of cost-effective, accessible screening technologies. While Pap smears have historically played a crucial role in reducing cervical cancer rates in high-income countries, their reliance on specialized personnel and laboratory infrastructure limits their feasibility in resource-constrained settings. To address these challenges, the World Health Organization (WHO) has updated its guidelines to include more accessible screening methods, aiming to increase coverage and promote early detection in underserved regions. WHO's Global Strategy for the Elimination of Cervical Cancer seeks to screen 70% of women with a high-performance test at ages 35 and 45 by 2030. This initiative highlights the organization's commitment to expanding global screening programs, reinforcing the market's growth potential.

Traditional cervical cancer screening methods, such as Pap smears, have long been the gold standard. However, they are increasingly being supplemented by technological advancements such as liquid-based cytology and high-risk HPV DNA testing. These approaches improve sample quality, enhance diagnostic accuracy, and reduce turnaround time, making early detection more effective.

The integration of artificial intelligence (AI) in cervical cancer diagnostics has been a game changer, revolutionizing screening efficiency. AI-driven tools can now analyze cytological images with high precision, identifying abnormal cells that could indicate pre-cancerous or cancerous lesions. For example, AI-powered diagnostic systems can automatically evaluate digitized cytology slides, flagging potential abnormalities for further clinical review. This not only reduces human error but also expedites diagnostic processes, leading to faster medical interventions.

AI's impact extends beyond diagnostics to treatment planning. With machine learning and predictive analytics, healthcare providers can better assess lesion progression and offer personalized treatment approaches. Technologies such as LEEP and cryotherapy benefit significantly from AI precision, ensuring minimally invasive, highly effective interventions with shorter recovery times. In regions where healthcare infrastructure is limited, AI-driven solutions help scale screening programs efficiently, making high-quality diagnostics and treatment more accessible.

Cervical Cancer Screening, Diagnostics, And Pre-cancerous Dysplasia Lesion Treatment Market Report Highlights:

• Based on type, the cervical cancer screening segment led the market with the largest revenue share of 48.29% in 2024 and is expected to grow at the fastest CAGR during the forecast period. Cervical cancer screening is essential for early detection and prevention, utilizing a variety of devices and technologies to enhance accuracy, accessibility, and patient outcomes. Traditional Pap smear collection tools remain a cornerstone of screening, particularly in areas lacking advanced diagnostic infrastructure
• The cervical cancer diagnostics market is anticipated to witness at a substantial CAGR during the forecast period, driven by advancements in biopsy devices and colposcopes, alongside increasing adoption and demand for these technologies. In December 2024, the Federal Capital Territory Administration introduced a colposcopy machine designed to enhance early detection and treatment of cervical cancer among women. This groundbreaking initiative is expected to revolutionize healthcare delivery in the region.
• North America dominated the market with the largest revenue share of 41.17% in 2024. North America has made remarkable progress in reducing cervical cancer incidence and mortality over the past several decades, primarily through extensive cervical cancer screening programs. These initiatives rely heavily on Pap smears (cytology) and, increasingly, human papillomavirus (HPV) testing. However, despite high overall screening rates in many regions, disparities persist in screening participation and follow-up care, particularly among underserved populations. To address these gaps, healthcare systems across North America are adopting innovative solutions. Recent FDA approvals for HPV self-collection tests, such as the cobas HPV and BD Onclarity HPV assays, present a promising alternative for women who may avoid traditional pelvic exams due to discomfort, cultural sensitivities, or past trauma

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Variables, Trends & Scope

• 3.1. Market Dynamics
  • 3.1.1. Market driver analysis
  • 3.1.2. Market restraint analysis
  • 3.1.3. Market opportunities analysis
• 3.2. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Analysis Tools
  • 3.2.1. Industry Analysis - Porter's
    • 3.2.1.1. Supplier power
    • 3.2.1.2. Buyer power
    • 3.2.1.3. Substitution threat
    • 3.2.1.4. Threat of new entrant
    • 3.2.1.5. Competitive rivalry
  • 3.2.2. PESTEL Analysis
    • 3.2.2.1. Political landscape
    • 3.2.2.2. Economic landscape
    • 3.2.2.3. Social landscape
    • 3.2.2.4. Technological landscape
    • 3.2.2.5. Environmental landscape
    • 3.2.2.6. Legal landscape

Chapter 4. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market, Qualitative Data Analysis

• 4.1. Screening Guidelines for Cervical Cancer
• 4.2. Utilization of Cervical Cancer Screening
• 4.3. WHO and Other Policy Board Positions
• 4.4. Barriers to Cervical Cancer Screening

Chapter 5. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market, Market Developments Analysis

• 5.1. Emerging Technology and Innovation Trends
• 5.2. Reimbursement Landscape
• 5.3. Incidence and Prevalence of Cervical Cancer
• 5.4. Total Eligible Population
• 5.5. Assessing Trends in HPV-Vaccinated Populations

Chapter 6. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market: Type Estimates & Trend Analysis

• 6.1. Type Market Share, 2024 & 2035
• 6.2. Segment Dashboard
• 6.3. Global Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market by Type Outlook
• 6.4. Cervical Cancer Screening
  • 6.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.4.2. Pap Smear Collection Devices
    • 6.4.2.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.4.3. HPV Testing Platforms
    • 6.4.3.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.4.4. Cytobrush
    • 6.4.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.4.5. Self-collection kits
    • 6.4.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Market estimates and forecast, 2018 to 2035 (USD Million)
• 6.5. Cervical Cancer Diagnostics
  • 6.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.5.2. Colposcopes
    • 6.5.2.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.5.3. Cervical Biopsy Devices
    • 6.5.3.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.5.4. Colposcopes with AI Imaging (Digital)
    • 6.5.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.5.5. Others
    • 6.5.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)
• 6.6. Pre-cancerous Lesion Treatment
  • 6.6.1. Market estimates and forecast, 2018 to 2035 (USD Million)
    • 6.6.1.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.6.2. LEEP (loop electrosurgical excision procedure) Machine
    • 6.6.2.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.6.3. Cryotherapy
    • 6.6.3.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.6.4. Thermal Ablation
    • 6.6.4.1. Market estimates and forecast, 2018 to 2035 (USD Million)
  • 6.6.5. Others
    • 6.6.5.1. Market estimates and forecast, 2018 to 2035 (USD Million)

Chapter 7. Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market: Regional Estimates & Trend Analysis, By Product, By Type, By End Use

• 7.1. Regional Market Share Analysis, 2024 & 2035
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2035:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts, 2018 to 2035 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts, 2018 to 2035 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts, 2018 to 2035 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts, 2018 to 2035 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts, 2018 to 2035 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts, 2018 to 2035 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Key company market share/position analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. F. Hoffmann-La Roche
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Technology Type benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. BD
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Technology Type benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Abbott
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Technology Type benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. QIAGEN
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Technology Type benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Hologic, Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Technology Type benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. CooperSurgical Inc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Technology Type benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. MedGyn Products, Inc
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Technology Type benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. WISAP Medical Technology GmbH
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Technology Type benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Liger Medical
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Technology Type benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Utah Medical Products, Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Technology Type benchmarking
    • 8.4.10.4. Strategic initiatives